Analysis of drug panels in urine samples can be challenging, and the trend towards larger panels including multiple
drug classes compounds the issues faced during method development.

This white paper examines a number of aspects of sample preparation, and their impact on the success of subsequent LC-MS-MS analysis of broad urine panels.